NCT01803867 - An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

January 31, 2015

Conditions

Multiple Sclerosis

Interventions

DRUG

rHIgM22

Administered via IV infusion

Trial Locations (17)

14642

Acorda Investigational Site, Rochester

22125

Acorda Investigational Site, Baltimore

37920

Acorda Investigational Site, Knoxville

46202

Acorda Investigational Site, Indianapolis

63131

Acorda Investigational Site, St Louis

66160

Acorda Investigational Site, Kansas City

80045

Acorda Investigational Site, Aurora

80112

Acorda Investigational Site, Centennial

90806

Acorda Investigational Site, Long Beach

95817

Acorda Investigational Site, Sacramento

98101

Acorda Investigational Site, Seattle

98122

Acorda Investigational Site, Seattle

04158

Acorda Investigational Site, Palo Alto

94305-5235

Acorda Investigational Site, Stanford

02905

Acorda Investigational Site, Providence

75390-9036

Acorda Investigational Site, Dallas

05401

Acorda Investigational Site, Burlington